Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised …

GJ Kahaly, RS Douglas, RJ Holt, S Sile… - The Lancet Diabetes & …, 2021 - thelancet.com
Background Thyroid eye disease manifests inflammation and treatment-resistant proptosis
and diplopia. Teprotumumab, an insulin-like growth factor-1 receptor inhibiting monoclonal …
被引用次数：133 相关文章

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised …

GJ Kahaly, RS Douglas, RJ Holt, S Sile, TJ Smith - 2021 - pubmed.ncbi.nlm.nih.gov
Background Thyroid eye disease manifests inflammation and treatment-resistant proptosis
and diplopia. Teprotumumab, an insulin-like growth factor-1 receptor inhibiting monoclonal …

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised …

GJ Kahaly, RS Douglas, RJ Holt, S Sile… - The lancet. Diabetes & …, 2021 - europepmc.org
Background Thyroid eye disease manifests inflammation and treatment-resistant proptosis
and diplopia. Teprotumumab, an insulin-like growth factor-1 receptor inhibiting monoclonal …

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised …

GJ Kahaly, RS Douglas, RJ Holt, S Sile… - The Lancet Diabetes & …, 2021 - Elsevier
Background Thyroid eye disease manifests inflammation and treatment-resistant proptosis
and diplopia. Teprotumumab, an insulin-like growth factor-1 receptor inhibiting monoclonal …